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Inhibition of the Canonical IKK/NFκB Pathway Sensitizes Human 
Cancer Cells to Doxorubicin
ABSTRACT
The NFκB family is composed by five subunits (p65/RelA, c‑Rel, RelB, p105‑p50/
NFκB1, p100‑p52/NFκB2) and controls the expression of many genes that participate 
in cell cycle, apoptosis, and other key cellular processes. In a canonical pathway, NFκB 
activation depends on the IKK complex activity, which is formed by three subunits (IKKa 
and IKKb and IKKg/NEMO). There is an alternative NFκB activation pathway that does 
not require IKKb or IKKg/NEMO, in which RelB is a major player. We report in a panel 
of human breast cancer cells that the IKK/NFκB system is generally overexpressed in 
breast cancer cells and there is heterogeneity in expression levels of individual members 
between different cell lines. Doxorubicin, an anticancer agent used in patients with 
breast cancer, activated NFκB and appeared to be less effective in cells expressing 
predominantly members of the canonical IKK/NFκB. Two NFκB inhibitors, bortezomib 
and NEMO‑Binding Domain Inhibitory Peptide, prevented doxorubicin‑induced NFκB 
activation and increased doxorubicin antitumor effects in BT‑474 cells. Transient 
down‑regulation of members of the canonical pathway (p65, p52, c‑Rel and IKKg/
NEMO) by siRNA in HeLa cells increased doxorubicin cytotoxicity. In contrast, silencing 
of RelB, a key subunit of the alternative pathway, had no evident effects on doxorubicin 
cytotoxicity. To conclude, NFκB inhibition sensitized cells to doxorubicin, implying 
directly p65, p52, c‑Rel and IKKg/NEMO subunits in chemoresistance, but not RelB. 
These findings suggest that selective inhibition of the canonical NFκB pathway is sufficient 
to improve doxorubicin antitumor effects.
INTRODuCTION
The	nuclear	 factor-κB	 (NFκB)	pathway	 controls	 the	 expression	of	many	 genes	 that	
participate	 in	 cell	 cycle,	 immune	 responses,	 angiogenesis,	 cell	 adhesion	 and	 apoptosis,	
relating	it	to	the	control	of	a	wide	variety	of	pathological	conditions.1,2	The	NFκB	family	
is	composed	of	five	subunits;	three	of	them	containing	a	transactivation	domain—p65/
RelA,	 c-Rel	 and	 RelB—and	 two	 others	 without	 it—p105-p50/NFκB1	 and	 p100-p52/
NFκB2.	There	 are	 two	 known	 NFκB	 activation	 pathways.	 A	 first	 pathway	 is	 termed	
classical	 or	 canonical,	 where	 NFκB	 activation	 depends	 on	 the	 IKK	 complex	 activity	
and	 IκB	 degradation.	 In	 resting	 cells	 NFκB	 proteins	 form	 cytoplasmic	 dimers	 associ-
ated	 to	 the	 inhibitory	 IκB	 proteins	 (IκB-a,	 IκB-b	 or	 IκB-e).	 IκBs	 mask	 the	 nuclear	
localization	signal	(NLS)	of	NFκB	proteins,	keeping	them	inactive	in	the	cytoplasm.	The	
canonical	pathway	is	activated	by	different	stimuli,	classically	proinflammatory	cytokines,	
whose	transduction	signal	activates	the	IKK	complex,	formed	by	three	subunits—IKKa	
and	 IKKb	 and	 IKKg/NEMO.	 After	 activation,	 IKKb	 phosphorylates	 inhibitory	 IκBs	
triggering	 their	 ubiquitination	 and	 subsequent	 proteasomal	 degradation.	 This	 releases	
NFκB	dimers—commonly	p65-p50	but	also	others	 involving	p52,	and	allows	 them	to	
translocate	 to	 the	nucleus,	where	 they	activate	 the	 transcription	of	 their	 target	genes.3,4	
The	 canonical	 pathway	 is	 principally	 related	 to	 inflammation,	 cell	 proliferation	 and	
survival	signals.	A	second	NFκB	activation	pathway,	named	alternative,	does	not	require	
the	subunits	IKKb	nor	IKKg/NEMO,	since	in	this	case	the	transduction	signal	converges	
on	the	protein	kinase	NIK,	which	activates	dimers	of	IKKa.	This	pathway	is	characterized	
by	the	absence	of	p65	or	c-Rel	subunits	and	by	the	presence	of	p100-RelB	heterodimers,	
in	which	p100	acts	as	the	inhibitory	subunit.	Phosphorylation	of	p100	by	IKKa	promotes	
its	 cleavage,	 releasing	 the	 fragment	 containing	 ankyrin	 repeats.	The	 resulting	p52-RelB	
dimer	translocates	to	the	nucleus,	where	it	activates	genes	involved	in	humoral	immunity	
and	cell	differentiation.3,4
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Preclinical	 and	 clinical	 data	 support	 a	 role	 for	 NFκB	 in	 the	
development	 and	 progression	 of	 human	 malignancies.5	 There	 is	
also	 increasing	 evidence	 that	 NFκB	 plays	 a	 role	 in	 chemoresist-
ance.6	Preclinical	studies	have	shown	that	several	chemotherapeutic	
agents	 activate	 the	 NFκB	 pathway.7,8	 The	 resulting	 expression	 of	
anti-apoptotic	 proteins	 regulated	 by	 NFκB	 limits	 then	 the	 anti-
tumor	 activity	 of	 cancer	 therapies.9	We	 focused	 the	 present	 work	
in	 studying	 the	role	of	NFκB	in	doxorubicin	resistance	 for	various	
reasons.	 First,	 doxorubicin	 is	 a	 chemotherapeutic	 agent	 from	 the	
anthracyclines	group	which	is	widely	used	for	breast	cancer	treatment	
as	well	as	in	other	malignancies.	Anthracyclines	are	topoisomerase	II	
inhibitors	 and	 produce	 DNA	 damage,	 that	 is	 a	 critical	 signal	 for	
NFκB	activation.10,11	Furthermore,	NFκB	inhibition	may	enhance	
the	 cytotoxicity	 of	 anthracyclines.12	 In	 addition	 to	 experimental	
observations,	we	and	others	have	reported	that	breast	cancer	patients	
with	constitutively	active	NFκB	in	tumor	cells	were	significantly	more	
resistant	to	doxorubicin-based	chemotherapy	than	patients	with	no	
basal	NFκB	activation.12	We	also	found	that	NFκB	appeared	to	be	
activable	during	chemotherapy	exposure	in	some	patients’	tumors.
Intense	efforts	in	the	development	of	NFκB	inhibitors	for	cancer	
treatment	 and	particularly	 for	 reverting	 chemoresistance	 justify	 the	
need	 for	 further	 characterization	 and	 understanding	 of	 the	NFκB	
pathway	in	human	cancer.	Here	we	show	that	there	is	a	great	diversity	
in	the	expression	of	individual	members	of	the	IKK/NFκB	pathway	
in	human	breast	cancer	cells	with	a	parallelism	between	a	conserved	
expression	 of	members	 of	 the	 canonical	 pathway	 and	 doxorubicin	
resistance.	 Notably,	 by	 using	 both	 pharmacological	 and	 genetic	
approaches,	inhibition	of	the	canonical	NFκB	pathway	was	sufficient	
to	increase	the	cytotoxicity	of	doxorubicin.
MATeRIAlS AND MeThODS
Cell lines and cultures.	 Six	 human	 breast	 cancer	 cell	 lines	
(MDA-MB-231,	 MDA-MB-453,	 MDA-MB-468,	 SK-BR-3,	
BT-474,	MCF-7),	 a	 human	 cervical	 cancer	 cell	 line	 (HeLa)	 and	 a	
mammary	epithelial	one	as	control	(MCF-10A)	were	purchased	from	
the	American	Type	Culture	Collection	and	cultured	at	37°C	with	5%	
CO2	in	DMEM	(MDA-MB-231,	MDA-MB-453,	MDA-MB-468,	
BT-474,	SK-BR-3,	HeLa)	or	DMEM/F12	(MCF-7)	 supplemented	
with	2mM	L-glutamine	and	10%	fetal	bovine	 serum.	For	BT-474,	
insulin	 (0.01mg/ml)	 was	 added.	 Line	 MCF-10A	 was	 cultured	 in	
MEMB	Basal	Medium	(Clonetics,	cat.	No.	CC-3151)	supplemented	
with	MEGM	Singlequots	(Clonetics,	cat.	No.	CC-4136):	2ml	BPE,	
500ng/ml	 hydrocortisone,	 10ng/ml	 hEGF	 and	 5mg/ml	 insulin.	
The	 rest	 of	 culture	medium	 and	 supplements	were	 obtained	 from	
Gibco-BRL.
Recombinant	 human	TNFa	 was	 purchased	 from	 Calbiochem.	
Bortezomib	 was	 kindly	 provided	 by	 Millennium	 Pharmaceuticals	
(Cambridge,	MA,	USA);	 10mM	 aliquots	 of	 drug	 in	DMSO	were	
stored	at	-20°C,	thawed,	and	diluted	just	before	use.	NEMO-Binding	
Domain	 Inhibitory	 Peptide	 was	 purchased	 from	Calbiochem	 (cat.	
No	480025).	Doxorubicin	(D1515)	and	all	chemicals	not	otherwise	
specified	below	were	purchased	from	Sigma.
MTS viability assay.	The	 effects	 of	 doxorubicin	 on	 the	 prolif-
eration	 and	 viability	 of	 breast	 cancer	 cells	 were	 studied	 using	 the	
colorimetric	 method	 provided	 by	 the	MTS-CellTiter	 96	 Aqueous	
Non-Radiactive	Cell	Proliferation	Assay	Kit	 (Promega).	MTS	assay	
is	 a	modification	 from	MTT	assay	 and	depends	 on	 two	 solutions:	
a	 tetrazolium	 compound	 (MTS)	 and	 an	 electron	 coupling	 reagent	
(phenazine	 methosulfate;	 PMS).	 MTS	 is	 bioreduced	 by	 cells	 into	
a	formazan	product.	The	conversion	of	MTS	into	aqueous,	soluble	
formazan	is	accomplished	by	dehydrogenase	enzymes	found	in	cells	
that	 are	metabolically	 active.	The	quantity	 of	 formazan	product	 as	
measured	by	the	amount	of	490	nm	absorbance	 is	directly	propor-
tional	to	the	number	of	living	cells	in	culture	(21).	We	performed	the	
MTS	assay	in	96-well	flat-bottomed	plates	(Nunc).	Approximately	1	
x	104	cells	were	seeded	in	100	ml	of	drug	free	media	and	incubated	
for	24h	before	drug	treatment.	100	ml	of	various	2x	drug	concentra-
tion	(1x	final	concentration)	were	added	for	times	from	24	to	48h.	
Forty	microliters	of	MTS/PMS	solution	were	added	to	the	wells,	and	
the	 cells	 were	 further	 incubated	 for	 2–4h.	The	 amount	 of	 soluble	
formazan	produced,	by	cellular	reduction	of	the	MTS,	was	measured	
by	 the	 absorbance	 on	 a	 microplate	 spectrophotometer	 (Molecular	
Dynamics)	 at	 490	 nm	 (test	 wavelength)	 and	 690	 nm	 (reference	
wavelength).	 The	 percentage	 of	 surviving	 cells	 was	 estimated	 by	
dividing	 the	 A490–A690	 nm	 of	 treated	 cells	 by	 the	 A490–A690	
nm	of	control	cells.	Approximate	IC50	values	were	determined	from	
the	dose	response	curve.	Data	were	derived	from	at	least	three	inde-
pendent	experiments.
Western blot.	 For	 cytoplasmic	 western	 blot	 assays,	 cells	 were	
cultured	in	6	well	plates	and	lysed	in	ice-cold	Nonidet	P-40	buffer	
[1%NP40,	50	mM	Tris-HCl	(pH	7.4),	150	mM	NaCl,	EDTA	5	mM	
containing	 5	mM	NaF,	 2	mM	Na3VO4,	 1	mM	PMSF,	Leupeptin	
5	mg/ml	and	Aprotinin	5	mg/ml].	After	incubating	for	30	min	at	4°C,	
the	 samples	were	 centrifuged,	 and	 the	 supernatant	was	kept	 as	 the	
NP-40-soluble	fraction.
Nuclear	 cell	 extracts	 were	 obtained	 essentially	 as	 described	
in	 ref.	 13.	 Samples	 (10	 mg/lane)	 were	 subjected	 to	 SDS-PAGE	
and	 transferred	 to	 nylon	 membranes	 (BioRad).	 Western	 blotting	
was	 carried	 out	 according	 to	 a	 standard	 procedure	 using	 horse-
radish	 peroxidase-conjugated	 secondary	 antibodies	 (Amersham).	
Target	 proteins	 were	 visualized	 after	 enhanced	 chemiluminescence	
treatment	 of	 membranes	 and	 subsequent	 exposure	 to	 X-ray	 film	
(Amersham).	The	following	primary	antibodies	were	used:	p65-NLS	
(MAB3026,	 Chemicon	 International,	 Inc.);	 p65	 (C-20,	 SC-372),	
p50	(H-119,	SC-7178),	p52	(K-27,	SC-298),	c-Rel	 (SC-71),	RelB	
(C-19,	 SC-226),	 IKKg	 (B-3,	 SC-8032),	 IκB-b	 (C-20,	 SC-945),	
IκB-e	 (M-121,	 SC-7156)	 and	 Nucleoline	 (MS-3,	 SC-8031)	 were	
obtained	from	Santa	Cruz	Biotechnology.	Antibodies	to	P-NFκBp65	
Ser536	 (1673031S),	 IKKa	 (2682),	 IKKb	 (2684), IKK	 g	 (2685),	
IκB-a	 (9242) are from Cell Signalling Technology; Monoclonal	 	 	 	 	 	 	
Anti-Beta-Actin	 (A-5316)	 and	 Monoclonal	 Anti-Alpha-Tubulin	
(T-5238)	 from	 Sigma,	 and	 anti-IKK	 gamma	 (residues	 2-13)	 from	
Abcam	Limited,	Novus-Biologicals.
Electrophoretic mobility shift assay (EMSA).	 Nuclear	 extracts	
were	obtained	as	for	Western	blotting	described	above.	EMSAs	were	
carried	 out	with	 a	 32P-labeled	NFκB	and	Oct1	probe	using	 a	Gel	
Shift	Assay	Core	System	kit	 (Promega),	 according	 to	 the	manufac-
turer’s	 instructions.14	After	 electrophoresis,	 gels	were	 fixed	 in	 10%	
acetic	acid-30%	ethanol	buffer	during	15	min,	and	then	dried	under	
vacuum	and	exposed	to	X-ray	 film	for	 three	days.	 In	some	cases,	a	
competition	assay	to	determine	sequence-specificity	of	protein-DNA	
interactions	 was	 performed	 by	 using	 25-fold	 excess	 of	 unlabeled	
NFκB-probe.	 For	 supershift	 analysis,	 anti-p50	 and	 anti-p65	 anti-
bodies	were	incubated	with	the	nuclear	extracts	for	15	min	prior	to	
the	addition	of	the	radiolabeled	probe.
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Immunofluorescence (IF).	 Briefly, cells were	 	 	
seeded	in	35-mm	tissue	culture	plates	on	sterile	glass	
coverslips.	 After	 appropriate	 treatments,	 cells	 were	
washed	with	PBS	and	fixed	with	a	mixture	of	meth-
anol	 and	 acetone	 for	 1	 h.	 After	 blocking	with	 1%	
(w/v)	bovine	serum	albumin	in	PBS	for	30	minutes	
at	 37°C,	 cells	were	 incubated	with	 anti-NFκB	p65	
antibody	 (1:200	 dilution)	 for	 one	 hour	 at	 room	
temperature.	Then,	 slides	were	washed	with	TBS-T	
and	 incubated	 with	 the	 secondary	 antibody	 Alexa	
546-coupled	 goat	 anti-rabbit	 IgG	 (1:1000	 dilu-
tion	 in	 PBS	 plus	 1%	 bovine	 serum	 albumin)	 for	
an	 additional	 hour	 (Invitrogen).	 The	 slides	 were	
further	 washed	 with	 TBS-T	 and	 then	 mounted	
using	 Mowiol	 coverslip	 solution	 (Mowiol	 4.88,	
Calbiochem).	For	co-localization	experiments	on	the	
same	 cells,	 double	 immunofluorescence	 techniques	
were	 used. Control and treated cells were fixed,	 	 	 	 	 	 	
permeabilized,	and	incubated	with	a	mixture	of	both	
anti-p50	rabbit	(1:100	dilution)	and	anti-p65	mouse	
(1:200	 dilution)	 antibodies.	 Secondary	 detection	
antibodies	were	Alexa	 488-coupled	 goat	 anti-rabbit	
IgG	 and	 Alexa	 555-coupled	 goat	 anti-mouse	 IgG	
(1:1000	dilutions)	generating	green	fluorescence	and	
red	fluorescence	for	polyclonal	and	monoclonal	anti-
bodies,	respectively.	Nuclei	were	stained	with	DAPI.
IF	slides	were	evaluated	in	10	intermediate-power	fields	of	slides	
(x250	optical	magnification)	and	photographed	using	DP71	digital	
camera	applied	to	a	Fluorescence	BX51	Olympus	microscope.
siRNA and transient cell transfection.	The	TranSilentTM	Human	
NFκBp65	 shRNA	Vector	 (Panomics,	Ref.	 SR1005)	was	purchased	
for	p65.	To	 generate	 knockdown	vectors	 for	 the	different	 subunits	
of	 NFκB,	 specific	 oligonucleotides	 encoding	 short	 hairpin	 RNAs	
were	ligated	into	pSUPERretro	vector	(OligoEngine),	following	the	
commercial	protocol.15	Oligonucleotides	used	were:	5'-GGTGATG
GATCTGAGTATA-3'	for	p52,	5'-CATACCCTTCTATCCAGAT-3
'	for	c-Rel,	5'-TTG	GAG	ATC	ATC	GAC	GAGT-3'	for	RelB	and	
5'-	GATTGTGATGGAGACCGTT-3'	 for	 IKKg/NEMO.	Bacterial	
colonies	were	pooled	and	used	for	plasmid	preparation.	Cells	at	50%	
confluence	were	transfected	with	6	mg	of	DNA	using	Lipofectamine	
2000	 Transfection	 Reagent	 (Invitrogen),	 according	 to	 the	 manu-
facturer’s	 specifications.	 After	 three	 days,	 cells	 were	 subjected	 to	
Western	blot	analysis	and	MTS	assay	in	the	presence	or	absence	of	
doxorubicin.
Statistical analysis.	Statistical	analysis	was	carried	out	with	SPSS	
version	 11.0	 (SPSS,	 Inc,	Chicago,	 IL).	To	 analyze	 correlations	 the	
unpaired	 t	 test	 was	 used	 to	 determine	 the	 statistical	 differences.	
Statistical	 tests	 were	 conducted	 at	 the	 two-sided	 0.05	 level	 of	
significance.
ReSulTS
Cytotoxicity of doxorubicin in breast cancer cells and IKK/
NFκB expression.	Doxorubicin	effects	on	cell	viability	were	tested	in	
a	panel	of	six	breast	cancer	cell	lines	(MDA-MB-231,	MDA-MB-453,	
MDA-MB-468,	 SK-BR-3,	 BT-474	 and	 MCF-7)	 by	 MTS	 assay	
(Fig.	1).	MDA-MB-231,	MDA-MB-453,	MDA-MB-468,	SK-BR-3	
cells	 showed	an	 IC50	at	48	h	 lower	 than	15	mM,	and	BT-474	and	
MCF-7	cell	 lines	had	an	IC50	~40–50	mM.	Based	on	these	 results,	
we	 considered	BT-474	 and	MCF-7	 cell	 lines	 relatively	 resistant	 to	
doxorubicin.	A	non	malignant	breast	epithelial	cell	line	(MCF-10A)	
was	also	assayed	by	MTS.	The	sensitivity	of	this	cell	line	appeared	to	
be	intermediate,	with	an	IC50	~20–25	mM	at	48	h.
We	 then	 assayed	 by	Western	 blot	 the	 expression	 of	 individual	
members	 of	 the	 IKK/NFκB	 system	 in	 our	 chosen	 panel	 of	 cell	
lines	 (Fig.	 2).	 Specifically,	 we	 assayed	NFκB	 subunits	 (p65/Rel-A,	
p50-105/NFκB1,	 p52-100/NFκB2,	 c-Rel,	 RelB)	 (Fig.	 2A),	 IKK	
complex	isoforms	(IKKa,	IKKb	and	IKKg/NEMO)	(Fig.	2B),	and	
NFκB	inhibitory	proteins	(IκB-a,	IκB-b,	IκB-e)	(Fig.	2C).	We	also	
used	 a	 p65	 antibody	 that	 recognizes	 the	 NLS	 of	 p65.	Therefore,	
the	 antibody	 selectively	 binds	 to	 the	 presumably	 activated	 form	
of	 NFκB	 (here	 named	 as	 p65-NLS).	 IKK/NFκB	 proteins	 were	
generally	 overexpressed	 in	malignant	 cell	 lines	 in	 comparison	with	
the	 non-malignant	 cell	 line.	 All	 tumor	 cell	 lines	 had	 similar	 levels	
of	p65.	For	other	subunits,	there	were	marked	differences	in	protein	
expression	 levels	 between	 different	 cell	 lines.	 There	 was	 higher	
expression	of	activated	p65-NLS	in	BT-474	cells	in	comparison	with	
others.	 c-Rel	 and	RelB,	both	with	 transactivation	domain,	 and	 the	
inhibitory	 subunit	p100	(Fig.	2A,	upper	band),	had	higher	expres-
sion	levels	in	MDA-MB-468	and	SK-BR-3	cells,	while	p52	showed	
lower	levels	in	SK-BR-3	and	especially	in	MCF-7;	subunit	p50	was	
lower	 in	 BT-474	 and	 p105	 (Fig.	 2A,	 upper	 band)	 showed	 similar	
expression	in	all	cell	lines.
The	expression	of	IKK	complex	isoforms	also	varied	among	cell	
lines.	In	some	cells,	a	shorter	(37	kDa)	band	was	recognized	by	an	
anti-C-terminal	IKKg/NEMO	antibody	independent	of	the	presence	
of	the	native	50kDa	band	that	corresponds	to	the	full	length	IKKg/
NEMO	protein.	This	37kDa	band	was	also	detected	with	an	anti-full	
length	IKKg/NEMO	antibody,	but	not	with	an	antibody	recognizing	
the	 N-terminal	 region	 of	 the	 protein	 (data	 not	 shown),	 further	
Figure 1. Doxorubicin effects on breast cancer cells. Cell viability MTS assay to test the effects 
of doxorubicin on six breast cancer cell lines (MDA‑MB‑231, MDA‑MB‑453, MDA‑MB‑468, 
SK‑BR‑3, BT‑474, MCF‑7) treated with the drug for 48 h. All values are means of independent 
triplicate experiments.
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indicating	 that	 the	 37	 kDa	 band	 represents	 an	 IKKg/NEMO	
fragment	 with	 a	 truncated	 N-terminus	 rather	 than	 C-terminus.	
Nevertheless,	 both	 Northern	 blot	 and	 RT-PCR	 assays	 (data	 not	
shown)	detected	only	one	mRNA	size	for	IKKg/NEMO,	suggesting	
the	 possibility	 that	 the	 shorter	 protein	 IKKg/NEMO	 isoform	 is	
generated	by	a	post-translational	event.	Expression	of	inhibitory	IκBs	
proteins	showed	that	IκB-a	was	higher	in	MDA-MB-453,	SK-BR-3,	
BT-474	and	MCF-7.	IκB-b	was	undetected	in	MDA-MB-468	and	
IκB-e	expression	was	similarly	expressed	in	all	malignant	cell	lines.
These	results	 show	heterogeneity	 in	the	expression	of	 individual	
members	of	the	IKK/NFκB	pathways.	A	lower	expression	of	members	
of	 the	alternative	NFκB	pathway,	p100	and	RelB,	was	observed	 in	
two	 cell	 lines,	BT-474	 and	MCF-7.	Globally,	 it	 appeared	 that	 cell	
lines	 with	 a	 predominant	 expression	 of	members	 of	 the	 canonical	
pathway,	such	as	BT-474	and	MCF-7,	were	less	sensitive	to	doxoru-
bicin.	However,	this	correlation	could	be	merely	coincidental.
Inhibition of NFκB by bortezomib and NBD inhibitory peptide 
enhanced doxorubicin sensivity in BT‑474 Cells.	The	 next	 set	 of	
experiments	was	 focused	 in	studying	a	possible	NFκB	involvement	
in	the	resistance	to	doxorubicin.	For	these	experiments,	BT-474	cells	
were	chosen	because	were	 relatively	 resistant	 to	doxorubicin	 in	our	
panel,	 had	 a	 predominant	 expression	 of	members	 of	 the	 canonical	
pathway	and	also	 showed	a	greater	 expression	of	NLSp65	 subunit.	
In	a	 first	 step,	NFκB-DNA	binding	activity	 following	doxorubicin	
treatment	was	 analyzed	 by	 EMSA.	 BT-474	 cells	 were	 treated	with	
15	mM	doxorubicin	or	with	10	ng/ml	TNFa	(as	a	positive	control).	
These	conditions	were	chosen	after	performing	time-response	assays	
and	selecting	the	doxorubicin	concentration	at	its	IC25.	Both	TNFa	
and	doxorubicin	induced	a	marked	NFκB	DNA	binding	compared	
with	untreated	 cells	 (Fig.	 3A).	 Specificity	was	 verified	by	 competi-
tion	with	 a	25-fold	 excess	of	unlabeled	NFκB-probe.	As	 shown	 in	
Figure	3A,	the	 indicated	NFκB-DNA complexes were substantially	 	 	 	
removed	by	adding	an	excess	of	cold	NFκB probe (specific probe).	 	 	 	
Similar	levels	of	the	control	oligonucleotide	
for	Oct1	 binding	 in	 the	 different	 samples	
confirm	 that	 the	 observed	 differences	 in	
NFκB activity are not due to differences in	 	 	 	 	 	 	 	
the	integrity	of	nuclear	extract	used	in	this	
experiment.	Additionally,	EMSA	supershift	
assay,	 with	 specific	 NFκB	 subunits	 anti-
bodies,	 showed	 that	 doxorubicin-induced	
NFκB	 contains	 at	 least	 the	 p50	 and	 p65	
subunits;	two	specific	bands	could	be	iden-
tified:	 the	 lower	 band	 as	 the	 p50/p50	
homodimer	and	the	upper	band	as	the	p50/
p65	 heterodimer	 (Fig.	 3B).	 Experiments	
of	 p65	 and	 p50	 co-localization were also	 	 	
performed	 by	 IF. The p65-p50 complexes	 	 	 	
(identified	 as	 yellow	merged	 signals)	 were	
detected	in	most	of	TNFa	or	doxorubicin	
treated	cells	(Fig.	3C).
We	 then	 studied	 whether	 blocking	
NFκB	 activation	 could	 improve	 doxoru-
bicin	 effects	 on	 cytotoxicity.	 To	 perform	
these	 studies	we	used	 two	different	NFκB	
inhibitors	 that	 act	 at	 different	 levels	 on	
the	 NFκB	 pathway:	 BTZ,	 a	 proteasome	
inhibitor16-18	 that	 prevents	 IκB-a	 degra-
dation,	 and	 therefore	 keeps	NFκB	dimers	 at	 the	 cytoplasm;	 and	 a	
NEMO-binding	domain-(NBD)	inhibitory	peptide,	which	consists	
on	 an	 amino-terminal	a-helical	 region	of	 IKKg/NEMO	associated	
with	a	carboxy-terminal	segment	of	IKKa	and	IKKb,	that	it	blocks	
the	 IKK	 complex	 formation.19,20	Molecular	 effects	 of	 both	NFκB	
inhibitors	 were	 assayed	 by	 Western	 blot.	 For	 these	 experiments,	
NFκB	 activation	was	 assayed	 using	 an	 antibody	 specific	 for	 phos-
phorylated	 p65	 (P-p65).	 p65	 is	 phosphorylated	 in	 Ser536	 in	 the	
C-terminal	transactivation	domain	during	the	phosphorylation	and	
degradation	 of	 IκBs.	Doxorubicin	 treatment	 resulted	 in	 both	 p65	
phosphorylation	and	IκB-a	degradation	(Fig.	4A).	Cells	were	treated	
with	1	mM	BTZ	or	with	10	mM	NBD-inhibitory	peptide	for	90	min,	
and	 then	 exposed	 to	 15	mM	doxorubicin	 or	 10	 ng/ml	TNFa	 for	
4	h.	Pre-incubation	with	BTZ	(Fig.	4B)	or	NBD-inhibitory	peptide	
(Fig.	4C)	prevented	doxorubicin	induced	p65	phosphorylation.
Cotreatment	 of	 BT-474	 cells	 with	 doxorubicin	 and	with	NBD	
or	BTZ	 reduced	 cell	 viability	 to	 a	 greater	 extent	 than	doxorubicin	
alone,	 NBD	 alone	 or	 BTZ	 alone.	 NFκB	 implication	 in	 cellular	
doxorubicin	 resistance	was	 shown	when	BT-474	 cells	 were	 treated	
with	 doxorubicin	 combined	 or	 not	 with	 NFκB	 inhibitors	 for	 48	
h	 and	 revealed	 in	 a	MTS	 assay	 (Fig.	 4D).	The	 combination	 with	
BTZ	 or	 NBD-inhibitory	 peptide	 enhanced	 by	 30%	 and	 40%,	
respectively,	 doxorubicin	 cytotoxicity.	 Notably,	 NBD-inhibitory	
peptide	plus	doxorubicin	resulted	 in	greater	effects	on	cell	viability	
than	 bortezomib	 plus	 doxorubicin.	 The	 observations	 that	
NBD-inhibitory	peptide	had	only	slight	effects	on	cell	viability	when	
used	alone,	while	it	markedly	enhanced	the	effects	on	doxorubicin,	
supported	 a	 role	 of	 NEMO	 in	 mediating	 doxorubicin	 resistance	
under	our	assayed	conditions.
Silencing p65, p52, c‑Rel and IKKg/NEMO but not RelB by 
siRNA potentiated doxorubicin cytotoxicity. The	 results	 obtained	
in	BT-474	 cells,	 including	 the	 relative	 resistance	 to	doxorubicin	 in	
a	 context	 of	 predominant	 expression	 of	members	 of	 the	 canonical	
Figure 2. Characterization of the NFκB pathway proteins expression in breast cancer cell lines. (A) The 
NFκB subunits. An anti‑activated p65 (NLS specific) antibody was also used. Western Blot of p50 shows 
a 50 kDa band and a 105 kDa precursor band. Western blot of p52 shows a 52 kDa band and a 
100  kDa precursor band. In both cases additional bands are also seen. (B) The three IKK isoforms 
and (C) the IκB proteins. Total extracts were obtained from six breast cancer cell lines under basal 
conditions. The epithelial MCF‑10A cell line was used as control.
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pathway	 and	 the	 chemosensitization	 obtained	 by	 NBD-inhibitory	
peptide	 (which	 should	 affect	 only	 the	 activation	 of	 the	 canonical	
pathway),	 suggested	 that	 the	 canonical	 pathway	 was	 involved	 in	
doxorubicin	resistance.	In	an	attempt	to	further	understand	the	role	
of	individual	IKK/NFκB	subunits	in	doxorubicin	resistance,	siRNA	
oligonucleotides	were	designed	for	selected	proteins	of	the	pathway.	
For	this	purpose,	HeLa	cells	were	chosen	for	the	siRNA	assays	due	to	
their	high	transfection	efficiency	compared	with	the	poor	efficiency	
achieved	 in	BT-474	 cells	 (data	 not	 shown).	HeLa	 cells	 are	 derived	
from	 cervix	 carcinoma,	 a	 tumor	 type	 also	 treatable	 with	 doxoru-
bicin.	Activation	of	NFκB	in	HeLa	cells	exposed	to	doxorubicin	was	
observed.	A	4	h	treatment	with	doxorubicin	induced	p65	phosphor-
ylation	and	concomitant	IκB-a	degradation	in	HeLa	cells	(Fig.	5A).	
NFκB	subunits	(p65,	c-Rel,	RelB,	p50,	p52,	p105)	were	assayed	by	
Western	blot	 in	HeLa	nuclear	 extracts	 treated	with	doxorubicin	or	
TNFa	(positive	control)	(Fig.	5B).	All	subunits	were	detected	in	the	
nucleus	 in	 response	 to	doxorubicin	or	TNFa	 exposure	 in	 a	higher	
extent	that	in	control	cells.
The	efficiency	of	the	designed	siRNA	oligonucleotides	was	tested	
by	Western	blot.	Cells	were	transfected	with	different	DNA	amounts	
and	 lysed	 at	 different	 times	 to	 find	 out	 the	 best	 combination.	 A	
decrease	of	protein	 levels	of	 the	corresponding	NFκB	subunits	was	
observed	 after	 three	 days	 of	 transfection	 with	 6	 mg	 of	 the	 corre-
sponding	siRNA	vector	(Fig.	6A).
We	 next	 performed	 viability	 assays,	 in	 which	 cells	 were	 trans-
fected	with	 the	 respective	 siRNA,	kept	 resting	 and	 three	days	 later	
treated	 with	 doxorubicin	 for	 24	 h.	 siRNA	 transfected	 cells	 did	
not	 exhibit	 evident	 effects	 on	 cell	 viability	 versus	 empty	 vector	
transfected	cells.	Transient	silencing	of	p65,	p52,	c-Rel	or	IKKg/NEMO	
enhanced	 approximately	 by	 30%	 the	 cytotoxicity	 of	 doxorubicin	
(%	cell	 viability:	 control	p65	84.2%	±	6.6%,	p65	51.5%	±	3.1%;	
control	 pSUPER	 85.9%	 ±	 3.5%,	 p52	 51.4%	 ±	 1.6%,	 c-Rel	
59.8%	 ±	 2.18%,	 IKKg/NEMO	 53%	 ±	 1.9%)(p	 <	 0.05,	 data	 not	
shown).	However,	silencing	RelB	subunit,	which	only	participates	in	
the	non	canonical	NFκB	pathway,	had	much	less	effect	on	doxoru-
bicin	cytotoxicity	(cell	viability	of	78%	±	7.55%)	(Fig.	6B).
DISCuSSION
In	 the	 present	 work	 we	 observed	 diversity	 in	 the	 expression	 of	
individual	 members	 of	 the	 IKK/NFκB	 pathway	 among	 different	
human	breast	cancer	cell	lines.	A	possible	link	between	predominant	
expression	 of	members	 of	 the	 canonical	 pathway	 and	 doxorubicin	
resistance	was	suggested	from	these	studies.	Furthermore,	inhibition	
of	 the	 canonical	NFκB	pathway	was	 sufficient	 to	 increase	doxoru-
bicin	 cytotoxicity	 in	 two	 different	 human	 tumor	 cell	 types	 (breast	
and	cervix	carcinomas)	as	assayed	by	a	pharmacological	and	a	genetic	
approach.
NFκB	activation	 is	 a	 frequent	event	mediated	by	many	chemo-
therapeutic	 agents,21	 which	 commonly	 implies	 the	 induction	 of	 a	
strong	 anti-apoptotic	 response	 that	 limits	 the	 efficacy	 of	 the	 treat-
ment.1	The	same	mechanism	of	resistance	can	occur	with	hormonal	
treatments	 and	 with	 radiation	 therapy.8,22	 We	 aimed	 our	 studies	
to	 gain	 further	 insight	 in	 the	 relationship	 between	 IKK/NFκB	
expression/activation	 and	 the	 cytotoxicity	 of	 doxorubicin	 in	 two	
human	cancer	types	where	this	agent	is	employed	in	clinical	settings.	
Figure 3. Doxorubicin NFκB‑DNA binding activity induction in BT‑474 breast cancer cells. (A) EMSA assay of nuclear protein extracts from BT‑474 cells 
treated with 15 mM doxorubicin or 10 ng/ml TNFa at selected times. Radiolabeled oligonucleotides probes containing NFκB (upper panel) or Oct1 (lower 
panel) DNA binding motifs were used. After treatments, a substantially enhanced NFκB binding complex was observed in the nuclear extract of cells. The 
specificity of the NFκB‑DNA complex was ascertained by competition study. (B) The position of NFκB‑DNA complexes containing p50/p65 or p50/p50      
dimers (as determined by EMSA supershift assays) are indicated. (C) After treatment, cells were stained by double antibody immunofluorescence. Nuclei            
of cells are stained with DAPI. The p65‑p50 complexes (identified by yellow merged signals) were detected in nuclei in most of TNFa treated cells. Similar 
findings were observed for doxorubicin‑treated cells.
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It	 is	 well	 known	 that	 anthracyclines,	 such	 as	 doxorubicin,	 target	
DNA	topoisomerase	II	resulting	in	DNA	damage,	a	critical	signal	to	
switch	on	NFκB.10	Moreover,	 it	has	been	previously	 reported	 that	
in	response	to	double	strand	DNA	breaks	IKKg/NEMO	is	retained	
in	the	nucleus,	where	it	is	modified	by	SUMO	and	phosphorylated	
by	 the	 ATM	 kinase,23	 then	 it	 translocates	 to	 the	 cytoplasm	 and	
joins	 IKKb	 and	 IKKa	 for	 IKK	 complex	 formation	 and	 NFκB	
activation.24,25	Consequently,	 it	was	hypothesized	that	doxorubicin	
efficiency	could	be	augmented	by	repressing	the	activation	of	NFκB.	
Along	this	line,	it	has	been	described	that	NFκB	inhibition	sensitizes	
tumour	 cells	 to	 anthracyclines	 therapy26	 and	 more	 specifically	 to	
doxorubicin	treatment.7,27-29	From	a	clinical	perspective,	we	recently	
showed	that	activation	of	NFκB,	determined	by	NFκB/p65	nuclear	
immunostaining	 in	 tumor	 cells,	 significantly	 correlated	with	 resist-
ance	to	anthracycline-based	chemotherapy	in	breast	cancer	patients.12	
Furthermore,	 the	 number	 of	 patients	 with	 NFκB/p65	 activation	
increased	 after	 chemotherapy	 exposure.	That	 study	 revealed	 a	 link	
between	 activation	 of	 the	 canonical	 pathway	 (using	 nuclear	 p65	
translocation	 as	 a	 surrogate	marker	 of	 activation)	 and	 resistance	 to	
anthracyclines.	Other	elegant	studies	have	reported	similar	findings	
in	breast	cancer	as	well	as	in	other	tumor	types.6,7,30	Notably,	NFκB/
bcl-2	pathway	has	been	shown	to	correlate	with	pathologic	complete	
response	to	doxorubicin-based	neoadjuvant	chemotherapy	in	human	
breast	cancer.6	These	novel	in	vivo	data	strongly	supported	a	role	of	
NFκB	 activation,	 and	 in	 particular	 of	 the	 canonical	 pathway,	 as	 a	
cellular	mechanism	of	resistance	to	anticancer	therapy	and	suggested	
that	NFκB/p65	was	inducible	by	chemotherapy	in	patients.
We	assayed	the	expression	of	most	of	the	proteins	participating	in	
the	 IKK/NFκB	pathways;	 the	 five	NFκB	members,	 the	 three	 IKK	
isoforms,	and	 three	of	 the	 inhibitory	 IκBs.	Many	of	 these	proteins	
were	overexpressed	in	breast	cancer	cell	 lines	compared	to	the	non-
malignant	breast	epithelial	cell	line	MCF-10A.	In	addition,	there	was	
heterogeneity	among	different	cell	lines.	MCF-10A cells, as assayed by	 	 	 	 	
MTS,	had	an	intermediate	degree	of	sensitivity	to	doxorubicin	with	
regards	to	our	panel	of	malignant	breast	cancer	cell	lines.	This	result	is	
similar	(i.e.,	viability	of	MCF-10A	cells	affected	by	anticancer	drugs	
to	a	similar	extend	than	some	malignant	cells)	to	findings	using	other	
agents.31	Although this part of the work was merely descriptive, it	 	 	 	 	 	 	 	 	 	
raised	several	observations	of	potential	importance	for	future	studies.	
First,	 the	 molecular	 mechanisms	 underlying	 the	 overexpression	 or	
the	 downmodulation	 (even	 to	 undetected	 levels)	 of	 key	 proteins	
of	 this	 system	 are	 largely	 unknown.	 In	 particular,	 a	 shorter	 form	
for	 IKKg/NEMO	 (~37	KDa)	 was	 detected	 in	 some	 lines	 by	 both	
an	 anti-full	 length	 IKKg/NEMO	antibody	 and	 an	 anti	C-terminal	
antibody,	while	another	antibody	against	the	N-terminal	extreme	did	
not	detected	it.	On	the	other	hand,	both	Northern	Blot	and	RT-PCR	
assays	 revealed	 a	 single	mRNA	 size	 for	 IKKg/NEMO.	 Altogether,	
these	 experiments	 suggest	 the	 possibility	 of	 a	 new	 short	 form	 for	
IKKg/NEMO	 protein	 as	 a	 result	 of	 post-translational	 processing.	
Second,	 two	 cell	 lines,	 MCF-7	 and	 BT-474	 had	 a	 conserved	
expression	of	all	the	key	members	of	the	canonical	pathway	assayed.	
These	 two	 cell	 lines	 were	 relatively	 resistant	 to	 doxorubicin,	 thus	
indirectly	 suggesting	 that	 the	 integrity	 of	 the	 canonical	 pathway	
might	be	related	to	resistance	to	this	agent.	Due	to	these	findings,	we	
focused	our	additional	studies	in	BT-474	breast	cancer	cells.
Figure 4. Effects of NFκB inhibitors on NFκB activity and on doxorubicin effects in BT‑474 cells. (A) Western blot of BT‑474 total protein extracts against 
phosphorylated p65 and IκB‑a proteins. Cells were treated with 15 mM doxorubicin or 10 ng/ml TNFa (positive control) for 4 h. b‑actin was used to check 
protein loading. In both cases, NFκB is activated. (B) Western blot of BT‑474 cells treated with BTZ for 90 min, and then exposed to 15 mM doxorubicin or 
10 ng/ml TNFa for 4 h. In both cases, pre‑incubation with BTZ decreased p65 phosphorylation compared with controls. (C) Western blot of BT‑474 cells 
treated with NBD‑inhibitory peptide for 90 min, and then exposed to 15 mM doxorubicin or 10 ng/ml TNFa for 4 h. Pre‑incubation with NBD‑inhibitory 
peptide before adding doxorubicin or TNFa decreased p65 phosphorylation compared with controls. (D) BT‑474 cells were treated with 15 mM doxorubicin 
combined or not with two different NFκB inhibitors: 10 mM NBD‑inhibitory peptide, and 1 mM BTZ for 48 h. Results were revealed by MTS assay and con‑
firmed twice more. The cytotoxicity of doxorubicin in combination with either BTZ or NBD‑inhibitory peptide was enhanced in a 30% and 40% respectively.
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In	 BT-474	 cells,	 doxorubicin	 promoted	 IκB-a	 degradation,	
concomitantly	with	p65	phosphorylation,	 and	 induction	of	NFκB	
DNA	binding.	We	then	investigated	the	chemosensitizing	effects	of	
two	different	NFκB	inhibitors;	BTZ	and	NBD-inhibitory	peptide.	
The	first	agent,	BTZ,	is	a	proteasome	inhibitor	already approved in	 	 	
many	countries	for	the	treatment	of	patients	with	multiple	myeloma	
and	in	further	clinical	development	in	multiple	tumor	types.	The	role	
of	BTZ	in	NFκB	inhibition	is	indirect	and	mediated	by	its	effect	in	
the	canonical	pathway.	Proteasome	inhibition	prevents	IκB	degrada-
tion	 and	 therefore	 abrogates	 p65	 nuclear	 translocation.	 However,	
BTZ	affects	many	other	key	intracellular	proteins	and	therefore	the	
effects	 on	NFκB	 are	 not	 the	 sole	mechanism	 of	 antitumor	 action	
of	 this	 agent.	 In	 a	 previous	 study	we	 also	 found	 that	MCF-7	 and	
BT-474	cells	were	the	most	resistant	to	BTZ.18	We	also	investigated	
here	 the	 effects	 of NEMO-binding domain-(NBD) inhibitory	 	 	 	
peptide,	which	selectively	blocks	the	canonical	pathway	by	disrupting	
the	IKK	complex.	Both	agents,	BTZ	and	NBD-	inhibitory	peptide,	
augmented	doxorubicin	cytotoxic	effects	by	30%	to	40%	under	our	
experimental	conditions.	Thus,	NFκB	inhibitors	improved	doxoru-
bicin	treatment	in	BT-474	breast	cancer	cells,	which	adds	additional	
support	 to	 the	 hypothesis	 of	 the	 NFκB	 pathway	 as	 involved	 in	
tumor	 resistance	 to	 doxorubicin,	 and	 pointed	 to	 a	 key	 role	 of	 the	
canonical	 pathway	 in	 this	 effect.	We	 cannot	 rule	 out	 that	 effects	
other	 than	NFkB	 inhibition	 contribute	 to	 this	 enhanced	 tumoro-
cidal	effect,	since	both	NBD	inhibitory	peptide	and	BTZ	when	used	
alone	reduced	cell	viability.	However,	the	effects	of	NBD	inhibitory	
peptide	on	cell	viability	were	modest	while	it	greatly	enhanced	doxo-
rubicin	effects.
We	 next	 performed	 small	 interfer-
ence	 RNA	 experiments	 in	HeLa	 cells	 to	
explore	 the	 role	 of	 individual	 members	
on	 doxorubicin	 response.	We	 confirmed	
that	doxorubicin	induced	IκB-a	degrada-
tion	 and	 p65	 phosphorylation,	 together	
with	nuclear	translocation	of	NFκB	subu-
nits	 (p65,	 c-Rel,	 RelB,	 p50,	 p52	 and	
p105).	 siRNA	assays	 against	 the	 selected	
NFκB	proteins	 -p65,	p52,	c-Rel-	as	well	
as	 with	 IKKg/NEMO,	 increased	 about	
30–40%	 doxorubicin	 cytotoxicity.	 The	
death	 increase	obtained	by	 silencing	p52	
is	in	line	with	a	recent	publication,32	which	
describes	that	p52/RelB	heterodimers	only	
participate	 in	 the	 alternative	 pathway,	
while	p52/p65	or	p52/c-Rel	heterodimers	
are	 controlled	 by	 IκB	 inhibitors	 and	
finally	 activated	 by	 the	 IKK	 complex	
in	 the	 canonical	 pathway.	 In	 contrast,	
silencing	 RelB,	 which	 participates	 selec-
tively	 in	 the	 alternative	 NFκB	 pathway,	
had	 only	 minor	 effects	 on	 doxorubicin	
cytotoxicity.	 Preliminary	 experiments	
using	 siRNA	 constructions	 in	 combina-
tion	with	another	chemotherapeutic	agent	
widely	used,	docetaxel	(Taxotere),	which	is	
also	known	to	activate	NFκB,7	suggested	
similar	results	(data	not	shown).
Our	results	indicate	that	selective	inhibition	of	the	chosen	subunits	
of	 the	classical	 IKKNFκB	pathway	was	sufficient	 to	 increase	doxo-
rubicin	antitumor	effects.	The	work	presented	here	reveals	diversity	
in	 expression	 of	 individual	 members	 of	 the	 IKK/NFκB	 pathway	
among	 different	 human	 breast	 cancer	 cell	 lines.	 This	 observation	
raises	 additional	 support	 to	 the	 need	 of	 further	 functional	 studies	
as	well	as	assays	in	tumor	samples	from	patients.	From	a	functional	
perspective,	inhibition	of	the	canonical	NFκB	pathway	was	sufficient	
to	 increase	 the	cytotoxicity	of	doxorubicin	 in	 two	different	human	
tumor	 cell	 types	 (breast	 and	 cervix	 carcinomas)	 as	 shown	 by	 two	
approaches	(pharmacological	and	genetic).	These	findings	show	that	
selective	inhibition	of	the	canonical	IKKNFκB	pathway	is	sufficient	
to	improve	doxorubicin	antitumor	effects	in	the	studied	models,	an	
observation	 that	 should	be	 taken	 into	account	 for	 further	develop-
ment	of	IKK/NFκB	inhibitors	as	chemosensitizing	agents.
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Figure 5. Doxorubicin induction of NFκB in HeLa cells. (A) Western blot from HeLa total extracts against 
P‑p65 and IκB‑a proteins. Cells were treated with 15 mM docorubicin or 10 ng/ml TNF‑a (positive con‑
trol) for 4 h. To check protein loading we used a‑tubulin. Results show p65 activation after the treatment. 
(B) HeLa nuclear extracts treated as in (A) were analyzed by Western blot with antibodies against p65, 
c‑Rel, RelB, p50/p100, and p52 proteins. All assayed proteins translocated to the nucleus in response to 
doxorubicin treatment. Nucleolin was used as a control. 
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